Icosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV Vaccine

Zinger Key Points
  • The Seattle-based company now expects its cash balance to be sufficient to fund operations into 2H 2025.
  • ICVX shares are up 11.2% at $8.75 during the premarket session on the last check Tuesday.

Icosavax Inc ICVX announced topline interim results from its Phase 1 trial of IVX-A12 against the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults

  • IVX-A12 was generally well-tolerated across all dosage groups.
  • Solicited local and systemic adverse events (AEs) were generally mild or moderate, without dose-limiting reactogenicity.
  • IVX-A12 induced robust immune responses against RSV and hMPV in older adults across dosage levels and with and without adjuvant.
  • When administered in combination, there was no evidence of immune interference between RSV and hMPV VLPs.
  • Across dosage groups, IVX-A12 induced geometric mean titers (GMTs) in RSV-A neutralizing antibody titers (nAbs) of up to 16,100 IU/mL compared to 2,600 IU/mL for placebo.
  • GMTs in RSV-B nAbs were up to approximately 8,300 IU/mL compared to 2,500 IU/mL for the placebo.
  • Across dosage groups, IVX-A12 induced GMTs in hMPV-A nAbs of up to roughly 3,300 assay units/mL compared to 900 assay units/mL for placebo. 
  • IVX-A12 induced GMTs in hMPV-B nAbs of up to 23,900 assay units/mL compared to 11,500 assay units/mL for placebo. 
  • Icosavax plans to initiate a Phase 2 trial for IVX-A12 in RSV and hMPV in mid-2023 and evaluate two formulations.
  • Pending the planned Phase 2 trial results, Icosavax intends to conduct an IVX-A12 hMPV human challenge clinical trial. 
  • This hMPV human challenge model is currently in development and builds on an established precedent in the RSV field.
  • In December, Icosavax reported durability data at six months; 12-month immunogenicity data is expected in mid-2023.
  • Icosavax has priced a $67.8 million registered direct offering with select healthcare investors. The Seattle-based company now expects its cash balance to be sufficient to fund operations into 2H 2025.  

Price Action: ICVX shares are up 11.2% at $8.75 during the premarket session on the last check Tuesday.

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapTop StoriesMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!